Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04590248 · ClinicalTrials.gov registry record · Phase 2
A Study of Adavosertib as Treatment for Uterine Serous Carcinoma
A Phase 2 study of Uterine Serous Carcinoma, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 2
- Development phase
- 109
- Enrollment target
- 20
- Study locations
NCT04590248: Completed Phase 2 study of Uterine Serous Carcinoma, sponsored by AstraZeneca.
NCT04590248 is a Phase 2 study of Uterine Serous Carcinoma that has completed, run by AstraZeneca. The registered enrollment target is 109 participants, above the 85-participant average among 4 other Uterine Serous Carcinoma trials with a reported enrollment target (28% higher). The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04590248, a Phase 2 study of Uterine Serous Carcinoma, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 109 participants
- Enrollment target
- 20
- Study locations
Study Summary
This Phase 2b study aims to evaluate the efficacy and safety of adavosertib, an inhibitor of the tyrosine kinase WEE1, in subjects with recurrent or persistent uterine serous carcinoma (USC) who have previously received at least 1 prior platinum-based chemotherapy regimen for the management of USC.
Primary Outcome
Per Response Evaluation Criteria in Solid Tumours (RECIST) v1.1 for target lesions (TLs) and assessed by computed tomography (CT) or magnetic resonance imaging (MRI): Complete response (CR), Disappearance of all target lesions; Partial response (PR), \>=30% decrease in the sum of the diameters of TL, taking as reference the baseline sum of diameters.
Conditions Studied
Interventions
- DRUG Adavosertib
Study Locations (20)
Other
- Research Site - Toronto
- Research Site - Dijon
- Research Site - Marseille
- Research Site - Nice
- Research Site - Pierre-Bénite
- Research Site - Saint-Herblain
California
- Research Site - Burbank
- Research Site - Duarte
- Research Site - La Jolla
- Research Site - West Hollywood
New York
- Research Site - New York
- Research Site - The Bronx
Washington
- Research Site - Spokane
- Research Site - Vancouver
Colorado
- Research Site - Aurora
Iowa
- Research Site - Iowa City
Louisiana
- Research Site - Covington
Massachusetts
- Research Site - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 109 participants |
| Start Date | 2020-11-30 |
| Est. Completion | 2023-02-07 |
| Phase | Phase 2 |
What the finished NCT04590248 record still lists
NCT04590248 is an interventional study that assigns participants to a tested intervention. The registered 109 participants enrollment target is mid-sized for trials with a published cap, above the 85-participant average among 4 other Uterine Serous Carcinoma trials with a reported enrollment target (28% higher).
The record links to 1 condition, with Uterine Serous Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which Adavosertib is the first listed.
NCT04590248 names 20 study sites across 10 states, led by Other, California, New York.
Frequently Asked Questions
What is clinical trial NCT04590248 about?
NCT04590248 is a clinical study titled "A Study of Adavosertib as Treatment for Uterine Serous Carcinoma". This Phase 2b study aims to evaluate the efficacy and safety of adavosertib, an inhibitor of the tyrosine kinase WEE1, in subjects with recurrent or persistent uterine serous carcinoma (USC) who have previously received at least 1 prior platinum-based chemotherapy regimen for the management of USC.
What is the current status of trial NCT04590248?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 109 participants. The study started on 2020-11-30. Estimated completion is 2023-02-07.
What conditions does trial NCT04590248 study?
This clinical trial studies the following conditions: Uterine Serous Carcinoma.
What interventions are being tested in trial NCT04590248?
The interventions under investigation include: Adavosertib (DRUG).
Who is sponsoring clinical trial NCT04590248?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04590248 being conducted?
This trial has 20 study locations across California, Colorado, Iowa, Louisiana, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Uterine Serous Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Azenosertib in Uterine Serous Carcinoma: Biomarker Study
RECRUITING · Phase 2
-
Trial of Maintenance With Niraparib- Uterine Serous Carcinoma
COMPLETED · Phase 2
-
A Study of Azenosertib (ZN-c3) in Women With Recurrent or Persistent Uterine Serous Carcinoma
COMPLETED · Phase 2
-
A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02421380 · 109 participants · NA
Characterization of Hyperpolarized Pyruvate MRI Reproducibility
- NCT04526600 · 109 participants · NA
Fidgeting and Attentional and Emotional Regulation in ADHD
- NCT04835584 · 109 participants · Phase 1
KRT-232 and TKI Study in Chronic Myeloid Leukemia
- NCT06626516 · 109 participants · Phase 1
Tebentafusp-tebn With LDT in Metastatic UM
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI